查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447030

到 2030 年二肽肽酶 4 抑制劑市場預測 - 各藥物類型、應用和地理位置的全球分析

Dipeptide Peptidase 4 Inhibitor Market Forecasts to 2030 - Global Analysis By Drug Type, Application and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球二肽肽酶 4 抑制劑市場規模為 113 億美元，預計到 2030 年將達到 156.9 億美元，預測期內複合CAGR為 4.8%。一類稱為二肽基肽酶 4 (DPP-4) 抑制劑的藥物用於治療第 2 型糖尿病。 DPP-4 酵素負責分解腸促胰島素激素，而腸促胰島素激素對於控制血糖水平至關重要。這些藥物透過阻斷DPP-4 來發揮作用，DPP-4 會增加腸促胰島素的作用，特別是胰高血糖素樣胜肽-1 (GLP-1)，它會增加胰島素分泌並降低胰高血糖素的產生。結果，血糖水平降低，葡萄糖調節增強。

根據美國糖尿病協會的說法，二肽基肽酶 4 (DPP-4) 抑制劑是治療第 2 型糖尿病的一類有價值的藥物。這些抑制劑透過靶向 DPP-4 酶，增強腸促胰島素激素的有效性，有助於改善血糖控制。

市場動態：

驅動因素：

糖尿病發生率上升

二肽基肽酶 4 (DPP-4) 抑制劑的市場受到全球糖尿病盛行率持續上升的顯著推動。到 2030 年，全球估計將有 5.37 億人患有糖尿病，對高效糖尿病藥物的需求日益成長。此外，DPP-4抑制劑透過為第2型糖尿病患者提供可行的治療選擇來滿足這一需求，從而促進市場的整體成長。

阻礙因素：

潛在的安全問題

儘管二肽基肽酶 4 (DPP-4) 抑制劑總體上具有良好的安全性，但仍引發了一些安全性問題。由於有報告指出胰臟炎和關節疼痛等不常見但危險的副作用，患者和醫療保健專業人員可能不願意服用某些藥物。此外，必須承認和理解這些可能的危害，以確保 DPP-4 抑制劑在業界的持續可信度和批准。

機會：

擴展治療指南和適應症

二肽基肽酶 4 (DPP-4) 抑制劑的潛在機會包括將這些藥物納入更新的治療指南以及可能擴大其適應症。此外，正在進行的研究和臨床試驗可能會擴大適應症以及市場成長和採用的新途徑，以檢驗 DPP-4 抑制劑在特定患者群體中或與其他療法相結合的優勢。

威脅：

價格壓力與普遍侵蝕

當品牌藥專利到期時，DPP-4抑制劑市場面臨學名藥侵蝕威脅的課題。當通常以較低成本提供的通用替代品可用時，價格壓力可能會增加。此外，生產品牌版本的製藥公司可能會因這種現象而導致獲利能力下降，這可能會影響他們在研發和行銷資源上的投資。

Covid-19 影響：

二肽基肽酶 4 (DPP-4) 抑制劑市場在許多方面受到了 COVID-19 大流行的影響。處方模式和病患依從性受到病患優先事項變化、醫療保健系統中斷和財務困難的影響。遠距醫療的採用急劇增加，影響了病患互動和藥品銷售的傳統動態。此外，儘管抗糖尿病藥物的需求仍然強勁，但市場仍存在波動。這凸顯了製藥公司需要保持創新和靈活性，以應對全球健康危機的持續影響。

西格列汀業務預計在預測期內成為最大的業務

預計西格列汀區隔市場將擁有最大的市場佔有率。西他列汀以多個品牌出售，是治療第 2 型糖尿病的常用處方藥。它透過抑制 DPP-4 酶發揮作用，從而顯著降低血糖水平。其良好的安全性、口服給藥的簡便性以及已證實的改善血糖控制的能力是其受歡迎的原因。此外，西格列汀憑藉其廣泛的用途和豐富的臨床經驗，在DPP-4抑制劑市場上佔有重要地位。

預計診所業務在預測期內複合CAGR最高

市場CAGR最高的是診所領域。這種模式顯示患者偏好和醫療保健提供方式發生了變化。診所因提供定期檢查、預防性護理和專門治療等各種醫療服務而變得越來越受歡迎。他們的特點是更容易獲得和方便的醫療服務。對門診護理的需求不斷成長以及對個人化和社區醫療保健的日益重視推動了診所的快速擴張。此外，由於效率高、等待時間短以及為患者提供個人化護理，診所的成長速度更快。

佔比最大的地區：

北美擁有二肽肽酶 4 (DPP-4) 抑制劑最大的市場佔有率。一類稱為 DPP-4 抑制劑的藥物用於治療第 2 型糖尿病。由於多種原因，北美在 DPP-4 抑制劑市場中佔有相當大的佔有率。首先，該地區 2 型糖尿病的高發生率加劇了對有效治療方案的需求。根據美國疾病管制與預防中心 (CDC) 的數據，大多數美國人（約 3,400 萬人）患有第 2 型糖尿病。此外，北美還擁有完善的醫療保健基礎設施，其中包括製藥公司、尖端的醫學研究設施和監管框架。

複合CAGR最高的地區：

預計二肽肽酶 4 (DPP-4) 抑制劑市場將以亞太地區最高的CAGR成長。一類稱為 DPP-4 抑制劑的藥物用於治療第 2 型糖尿病。亞太地區包括中國、印度、日本、澳洲等國。由於多種因素，亞太地區 DPP-4 抑制劑市場正在快速成長。該地區有很多人有患 2 型糖尿病的風險，或者已經被診斷出患有這種疾病，而且人口正在迅速成長。此外，這種人口趨勢也為 DPP-4 抑制劑等糖尿病藥物創造了相當大的市場。

主要進展：

2024 年 2 月，諾華宣布已達成協議，將自願公開收購要約收購 MorphoSys AG。MorphoSys AG 是一家總部位於德國、開發腫瘤學創新藥物的全球生物製藥公司。根據一份新聞聲明，此次收購須滿足慣例成交條件，包括收購要約中所投標流通股的 65% 的最低接受門檻以及監管部門的批准。

2024 年 2 月，美國新澤西州羅韋市 Merck & Co., Inc. 的子公司默克動物保健公司（在美國和加拿大境外稱為默沙東動物保健公司）宣布已簽署收購水產品業務的最終協議以13 億美元現金收購Elanco Animal Health Incorporated，其中包括針對水生物種的藥物和疫苗、營養品和補充劑的創新組合；位於加拿大和越南的兩個相關水產生產設施；以及智利的一個研究機構。

2023 年 11 月，勃林格殷格翰和 IBM 宣布達成協議，勃林格殷格翰將能夠利用 IBM 的基礎模型技術來發現新型候選抗體，以開發有效的療法。勃林格殷格翰將使用 IBM 開發的預訓練人工智慧模型，該模型將根據勃林格殷格翰的其他專有資料進行進一步微調。

我們的報告提供了什麼：

  • 區域和國家層面的市場佔有率評估
  • 對新進入者的策略建議
  • 涵蓋2021年、2022年、2023年、2026年及2030年的市場資料
  • 市場趨勢（促進因素、限制因素、機會、威脅、課題、投資機會和建議）
  • 根據市場預測提出關鍵業務部門的策略建議
  • 競爭性景觀美化繪製主要共同趨勢
  • 公司概況，包括詳細的策略、財務狀況和最新發展
  • 反映最新技術進步的供應鏈趨勢

免費客製化產品：

本報告的所有客戶都將有權獲得以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 個）
    • 關鍵參與者的 SWOT 分析（最多 3 個）
  • 區域區隔
    • 根據客戶的興趣對任何主要國家的市場估計、預測和CAGR（註：取決於可行性檢查）
  • 競爭基準化分析
    • 根據產品組合、地理分佈和策略聯盟對主要參與者基準化分析

目錄

第 1 章：執行摘要

第 2 章：前言

  • 抽象的
  • 股東
  • 研究範圍
  • 研究方法論
    • 資料探勘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 研究來源
    • 主要研究來源
    • 二手研究來源
    • 假設

第 3 章：市場趨勢分析

  • 介紹
  • 促進要素
  • 限制
  • 機會
  • 威脅
  • 應用分析
  • 新興市場
  • Covid-19 的影響

第 4 章：波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭競爭

第 5 章：全球二肽肽酶 4 抑制劑市場：依藥物類型

  • 介紹
  • 西格列汀
  • 維格列汀
  • 沙格列汀
  • 利格列汀
  • 吉格列汀
  • 阿格列汀
  • 特力利汀
  • 其他藥物類型

第 6 章：全球二肽肽酶 4 抑制劑市場：依應用分類

  • 介紹
  • 醫院
  • 診所
  • 其他應用

第 7 章：全球二肽肽酶 4 抑制劑市場：依地理位置

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太地區其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第 8 章：主要進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 擴充
  • 其他關鍵策略

第 9 章：公司概況

  • Merck
  • Boehringer Ingelheim
  • Novartis
  • AstraZeneca
  • GlaxoSmithKline
  • Eli Lilly and Company
  • Pfizer
  • Sanofi
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals
Product Code: SMRC25291

According to Stratistics MRC, the Global Dipeptide Peptidase 4 Inhibitor Market is accounted for $11.3 billion in 2023 and is expected to reach $15.69 billion by 2030 growing at a CAGR of 4.8% during the forecast period. A class of drugs called dipeptidyl peptidase 4 (DPP-4) inhibitors is used to treat type 2 diabetes. The enzyme DPP-4 is responsible for the breakdown of incretin hormones, which are essential for controlling blood sugar levels. These drugs work by blocking DPP-4, which increases the effect of incretins, specifically glucagon-like peptide-1 (GLP-1), which raises insulin secretion and lowers glucagon production. As a result, blood sugar levels are lowered, and glucose regulation is enhanced.

According to the American Diabetes Association, Dipeptidyl Peptidase 4 (DPP-4) Inhibitors represent a valuable class of medications for the management of type 2 diabetes. These inhibitors, by targeting the DPP-4 enzyme, enhance the effectiveness of incretin hormones, contributing to improved blood sugar control.

Market Dynamics:

Driver:

Rising incidence of diabetes

The market for dipeptidyl peptidase 4 (DPP-4) inhibitors is significantly driven by the ongoing worldwide rise in the prevalence of diabetes. By 2030, there will be 537 million people worldwide estimated to have diabetes, creating a growing need for efficient diabetes medications. Furthermore, DPP-4 inhibitors meet this need by providing a workable treatment option for individuals with type 2 diabetes, thereby contributing to the overall growth of the market.

Restraint:

Potential safety issues

Dipeptidyl Peptidase 4 (DPP-4) inhibitors have raised some safety concerns despite having a generally good safety profile. Patients and healthcare professionals may be reluctant to take certain medications due to reports of uncommon but dangerous side effects, such as pancreatitis and joint pain. Moreover, it is imperative to acknowledge and comprehend these possible hazards in order to guarantee the sustained credibility and approval of DPP-4 inhibitors within the industry.

Opportunity:

Extending treatment guidelines and indications

Potential opportunities for Dipeptidyl Peptidase 4 (DPP-4) inhibitors include the inclusion of these drugs in updated treatment guidelines and the possible expansion of their indications. Additionally, expansion of indications and new paths for market growth and adoption may result from ongoing research and clinical trials examining the advantages of DPP-4 inhibitors in particular patient populations or in conjunction with other therapies.

Threat:

Price pressures and generic erosion

When the patents for branded drugs expire, the DPP-4 inhibitor market faces challenges from the threat of generic erosion. Price pressure may increase when generic alternatives, which are usually provided at a lower cost, are available. Furthermore, pharmaceutical companies that produce the branded versions may see a decrease in profitability as a result of this phenomenon, which could have an effect on their investment in R&D and marketing resources.

Covid-19 Impact:

The Dipeptidyl Peptidase 4 (DPP-4) inhibitor market has been impacted by the COVID-19 pandemic in many ways. Prescription patterns and patient adherence have been impacted by changes in patient priorities, disruptions in healthcare systems, and financial difficulties. The adoption of telehealth has increased dramatically, impacting the conventional dynamics of patient interactions and pharmaceutical sales. Additionally, the market has fluctuated even though the demand for anti-diabetic drugs has remained strong. This highlights the need for pharmaceutical companies to remain innovative and flexible in order to deal with the ongoing effects of the global health crisis.

The Sitagliptin segment is expected to be the largest during the forecast period

It is projected that the sitagliptin segment will have the largest market share. Sitagliptin, sold under several brand names, is a commonly prescribed drug for the treatment of type 2 diabetes. It works by inhibiting the DPP-4 enzyme, which significantly lowers blood sugar levels. Its favorable safety profile, ease of oral administration, and proven ability to improve glycemic control are the reasons for its popularity. Moreover, sitagliptin has a strong hold in the DPP-4 inhibitor market thanks to its broad usage and wealth of clinical experience.

The Clinics segment is expected to have the highest CAGR during the forecast period

The market's highest CAGR has been seen in the clinic segment. This pattern points to a change in patient preferences and the ways that healthcare is delivered. Clinics are becoming more and more popular for offering a variety of medical services, such as regular check-ups, preventive care, and specialized treatments. They are distinguished by their more easily accessible and convenient healthcare services. The rapid expansion of clinics has been driven by the growing need for outpatient care as well as the growing emphasis on individualized and community-based healthcare. Additionally, clinics are growing more rapidly because of the efficiency, shorter wait times, and individualized care they provide to their patients.

Region with largest share:

North America holds the largest market share for dipeptide peptidase 4 (DPP-4) inhibitors. A class of drugs called DPP-4 inhibitors is prescribed to treat type 2 diabetes. For a number of reasons, North America commands a sizable portion of the DPP-4 inhibitor market. First off, the need for efficient treatment options is fueled by the high rate of type 2 diabetes in the area. The majority of Americans with diabetes, approximately 34 million, have type-2 diabetes, according to the Centers for Disease Control and Prevention (CDC). Furthermore, North America also boasts a well-established healthcare infrastructure, which includes pharmaceutical companies, cutting-edge medical research facilities, and regulatory frameworks.

Region with highest CAGR:

The dipeptide peptidase 4 (DPP-4) inhibitor market is anticipated to grow at the highest CAGR in the Asia-Pacific region. A class of drugs called DPP-4 inhibitors is prescribed to treat type 2 diabetes. The nations of China, India, Japan, Australia, and other countries are included in the Asia-Pacific region. The Asia-Pacific DPP-4 inhibitor market is growing at a rapid rate due to a number of factors. There are many people in the area who are either at risk of developing type-2 diabetes or who have already been diagnosed with the disease, and the population is growing quickly. Moreover, a sizeable market is created for diabetes drugs, such as DPP-4 inhibitors, by this demographic trend.

Key players in the market

Some of the key players in Dipeptide Peptidase 4 Inhibitor market include Merck, Boehringer Ingelheim, Novartis, AstraZeneca, GlaxoSmithKline, Eli Lilly and Company, Pfizer, Sanofi, Bristol-Myers Squibb and Takeda Pharmaceuticals.

Key Developments:

In February 2024, Novartis announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. According to a press statement, the acquisition, which is subject to customary closing conditions, including a minimum acceptance threshold of 65 percent of outstanding shares tendered in the takeover offer and regulatory approvals.

In February 2024, Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile.

In November 2023, Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM's foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. Boehringer will be using an IBM-developed, pre-trained AI model that will be further fine-tuned on additional Boehringer proprietary data.

Drug Types Covered:

  • Sitagliptin
  • Vildagliptin
  • Saxagliptin
  • Linagliptin
  • Gemigliptin
  • Anagliptin
  • Teneligliptin
  • Other Drug Types

Applications Covered:

  • Hospitals
  • Clinics
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Dipeptide Peptidase 4 Inhibitor Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Sitagliptin
  • 5.3 Vildagliptin
  • 5.4 Saxagliptin
  • 5.5 Linagliptin
  • 5.6 Gemigliptin
  • 5.7 Anagliptin
  • 5.8 Teneligliptin
  • 5.9 Other Drug Types

6 Global Dipeptide Peptidase 4 Inhibitor Market, By Application

  • 6.1 Introduction
  • 6.2 Hospitals
  • 6.3 Clinics
  • 6.4 Other Applications

7 Global Dipeptide Peptidase 4 Inhibitor Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Merck
  • 9.2 Boehringer Ingelheim
  • 9.3 Novartis
  • 9.4 AstraZeneca
  • 9.5 GlaxoSmithKline
  • 9.6 Eli Lilly and Company
  • 9.7 Pfizer
  • 9.8 Sanofi
  • 9.9 Bristol-Myers Squibb
  • 9.10 Takeda Pharmaceuticals

List of Tables

  • Table 1 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 3 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
  • Table 4 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
  • Table 5 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
  • Table 6 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
  • Table 7 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
  • Table 8 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
  • Table 9 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
  • Table 10 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 11 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
  • Table 12 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 13 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 14 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 15 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
  • Table 16 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 17 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
  • Table 18 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
  • Table 19 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
  • Table 20 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
  • Table 21 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
  • Table 22 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
  • Table 23 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
  • Table 24 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 25 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
  • Table 26 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 27 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 28 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 29 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
  • Table 30 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 31 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
  • Table 32 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
  • Table 33 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
  • Table 34 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
  • Table 35 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
  • Table 36 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
  • Table 37 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
  • Table 38 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 39 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
  • Table 40 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 41 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 42 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 43 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 45 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
  • Table 46 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
  • Table 47 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
  • Table 48 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
  • Table 49 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
  • Table 50 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
  • Table 51 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
  • Table 52 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 53 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
  • Table 54 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 55 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 56 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 57 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
  • Table 58 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 59 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
  • Table 60 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
  • Table 61 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
  • Table 62 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
  • Table 63 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
  • Table 64 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
  • Table 65 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
  • Table 66 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 67 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
  • Table 68 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 69 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 70 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 71 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
  • Table 72 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 73 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
  • Table 74 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
  • Table 75 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
  • Table 76 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
  • Table 77 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
  • Table 78 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
  • Table 79 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
  • Table 80 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 81 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
  • Table 82 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 83 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 84 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)